Neuralink, a pioneering implant company co founded by Elon Musk, has announced that it has obtained clearance from the U.S. Food and Drug Administration (FDA) to commence trials on humans using its microchips.
Neuralink’s microchips, which have been tested on monkeys, can decode brain impulses and transfer data through Bluetooth. The chips are designed to empower disadvantaged people by addressing the likes of paralysis and blindness, allowing the patients to interact with technology. Clinical studies for human usage are on the horizon as the company overcomes safety hurdles faced during the FDA clearance procedure.
The FDA certification was described by Neuralink as a “important first step,” and it expressed thanks for the joint efforts of their team and the regulatory agency. While the firm would not share specifics on participant recruitment for the trials, it did promise the public that safety, accessibility, and dependability will be prioritized throughout the engineering process.
Neuralink also admits to having a propensity to overstate the speed of its execution, which it intends to rectify in the future. While the firm is not currently actively recruiting trial participants, it has pledged to publish further information in the near future.
The sources for this piece include an article in BBC.
